Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes.

Xu L, Cai L, Chen X, Jiang X, Chong H, Zheng B, Wang K, He J, Chen W, Zhang T, Cheng M, He Y, Liu K.

Antimicrob Agents Chemother. 2013 Oct;57(10):4963-70. doi: 10.1128/AAC.00758-13. Epub 2013 Jul 29.

2.

The use of hairpin DNA duplexes as HIV-1 fusion inhibitors: synthesis, characterization, and activity evaluation.

Xu L, Jiang X, Xu X, Zheng B, Chen X, Zhang T, Gao F, Cai L, Cheng M, Keliang Liu.

Eur J Med Chem. 2014 Jul 23;82:341-6. doi: 10.1016/j.ejmech.2014.05.068. Epub 2014 May 29.

PMID:
24927054
3.

Peptide and non-peptide HIV fusion inhibitors.

Jiang S, Zhao Q, Debnath AK.

Curr Pharm Des. 2002;8(8):563-80. Review.

PMID:
11945159
4.

Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.

Yu X, Lu L, Cai L, Tong P, Tan S, Zou P, Meng F, Chen YH, Jiang S.

J Virol. 2012 Jan;86(1):589-93. doi: 10.1128/JVI.05066-11. Epub 2011 Oct 19.

5.

DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity.

Xu L, Zhang T, Xu X, Chong H, Lai W, Jiang X, Wang C, He Y, Liu K.

Nucleic Acid Ther. 2015 Aug;25(4):219-25. doi: 10.1089/nat.2015.0535.

6.

Structural basis of potent and broad HIV-1 fusion inhibitor CP32M.

Yao X, Chong H, Zhang C, Qiu Z, Qin B, Han R, Waltersperger S, Wang M, He Y, Cui S.

J Biol Chem. 2012 Aug 3;287(32):26618-29. doi: 10.1074/jbc.M112.381079. Epub 2012 Jun 7.

7.

Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.

Yu F, Lu L, Du L, Zhu X, Debnath AK, Jiang S.

Viruses. 2013 Jan 11;5(1):127-49. doi: 10.3390/v5010127. Review.

8.

Discovery of small molecule fusion inhibitors targeting HIV-1 gp41.

Zhou G, Chu S.

Curr Pharm Des. 2013;19(10):1818-26. Review.

PMID:
23092284
9.

Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.

Chong H, Yao X, Qiu Z, Qin B, Han R, Waltersperger S, Wang M, Cui S, He Y.

J Biol Chem. 2012 Jun 8;287(24):20281-9. doi: 10.1074/jbc.M112.354126. Epub 2012 Apr 16.

10.

Identification of minimal sequence for HIV-1 fusion inhibitors.

Nishikawa H, Oishi S, Fujita M, Watanabe K, Tokiwa R, Ohno H, Kodama E, Izumi K, Kajiwara K, Naitoh T, Matsuoka M, Otaka A, Fujii N.

Bioorg Med Chem. 2008 Oct 15;16(20):9184-7. doi: 10.1016/j.bmc.2008.09.018. Epub 2008 Sep 10.

PMID:
18819810
11.

Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.

Zhou G, Wu D, Snyder B, Ptak RG, Kaur H, Gochin M.

J Med Chem. 2011 Oct 27;54(20):7220-31. doi: 10.1021/jm200791z. Epub 2011 Oct 3. Erratum in: J Med Chem. 2011 Dec 22;54(24):8713.

12.

Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.

An T, Ouyang W, Pan W, Guo D, Li J, Li L, Chen G, Yang J, Wu S, Tien P.

Antiviral Res. 2012 Jun;94(3):276-87. doi: 10.1016/j.antiviral.2012.02.014. Epub 2012 Mar 8.

PMID:
22426469
14.

A homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion.

Smeulders L, Bunkens L, Vereycken I, Van Acker K, Holemans P, Gustin E, Van Loock M, Dams G.

Methods Mol Biol. 2013;1030:11-7. doi: 10.1007/978-1-62703-484-5_2.

PMID:
23821256
15.

Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.

Chao L, Lu L, Yang H, Zhu Y, Li Y, Wang Q, Yu X, Jiang S, Chen YH.

PLoS One. 2013 May 31;8(5):e66156. doi: 10.1371/journal.pone.0066156. Print 2013.

16.

An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.

Liu Y, Ke Z, Wu KY, Liu S, Chen WH, Jiang S, Jiang ZH.

ChemMedChem. 2011 Sep 5;6(9):1654-64. doi: 10.1002/cmdc.201100149. Epub 2011 Jun 17.

PMID:
21688394
17.

Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.

Oishi S, Ito S, Nishikawa H, Watanabe K, Tanaka M, Ohno H, Izumi K, Sakagami Y, Kodama E, Matsuoka M, Fujii N.

J Med Chem. 2008 Feb 14;51(3):388-91. doi: 10.1021/jm701109d. Epub 2008 Jan 16.

PMID:
18197613
18.

d(TGGGAG) with 5'-nucleobase-attached large hydrophobic groups as potent inhibitors for HIV-1 envelop proteins mediated cell-cell fusion.

Chen W, Xu L, Cai L, Zheng B, Wang K, He J, Liu K.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5762-4. doi: 10.1016/j.bmcl.2011.08.007. Epub 2011 Aug 8.

PMID:
21873060
19.

Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.

He Y, Liu S, Jing W, Lu H, Cai D, Chin DJ, Debnath AK, Kirchhoff F, Jiang S.

J Biol Chem. 2007 Aug 31;282(35):25631-9. Epub 2007 Jul 6.

20.

Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.

Chong H, Yao X, Qiu Z, Sun J, Zhang M, Waltersperger S, Wang M, Liu SL, Cui S, He Y.

FASEB J. 2013 Mar;27(3):1203-13. doi: 10.1096/fj.12-222547. Epub 2012 Dec 11.

PMID:
23233535

Supplemental Content

Support Center